Entity
Beacon Biosignals
Beacon Biosignals, founded by MIT-affiliated researchers Jake Donoghue and Jarrett Revels, is developing an AI-driven platform to map brain activity during sleep for disease diagnosis and treatment.
Importance: 30%Confidence: 70%Mentions: 1Updated: August 3, 2026
## Overview
Beacon Biosignals is a company developing an AI-driven platform to map brain activity during sleep, aimed at helping diagnose and treat disease (MIT News, May 1). It was founded by Jake Donoghue (PhD '19, MIT) and Jarrett Revels, a former MIT researcher (MIT News, May 1).
## Technology
The company's platform focuses on analyzing brain signals during sleep using AI, positioning it within the growing intersection of neuroscience, wearable/biosignal data, and AI-driven diagnostics.
## Why It Matters
Beacon Biosignals represents a notable example of MIT-spinout biotech/AI convergence, part of a broader wave of AI-driven diagnostic platforms (alongside Aidoc Medical and others) applying machine learning to complex biological signal data for disease diagnosis and treatment. Sleep-related neurological data has significant commercial applications spanning neurological disorders, mental health, and broader wellness/consumer health markets.
## Developments to Watch
- Clinical validation studies and regulatory pathway (FDA clearance, etc.)
- Commercial partnerships with hospitals, sleep clinics, or wearable device makers
- Funding rounds and company growth
- Specific disease targets and diagnostic use cases